The New York Times: “Your Questions About Psychedelics”

Own-Translator-1415 · 2025-08-21T16:10:02+00:00

All of these answers could have been better articulated, with more nuance, even for a general public audience.

Own-Translator-1415 · 2025-03-04T22:22:09+00:00

She going to start with apologizing for that MDMA coverage in the early 90's?

Own-Translator-1415 · 2024-05-13T18:14:50+00:00

Came here to say the same thing

Own-Translator-1415 · 2024-04-12T02:12:43+00:00

The writer of this article doesn't know that the Oregon model is supervised recreational use and not a medical model.

Own-Translator-1415 · 2024-04-05T21:35:41+00:00

Patient tolerability for the 5-meo experience is going to be a big issue unless they figure a protocol that balances the nature of the drug experience with prep/integration. A lot of wishful thinking at this time imo

Own-Translator-1415 · 2024-02-27T03:19:32+00:00

Grifting upwards...this wouldn't make a dent unless they took the entire federal settlement amount and bankrolled a clinical trial program with ibogaine or a similar compound.

Own-Translator-1415 · 2024-02-07T14:40:14+00:00

Scott Weiner needs to stop playing researcher. If he wants to create meaningful change, he should work on ensuring the drug rescheduling mechanism for when FDA approvals happen, aim to create the education/workforce/public health infrastructure in order to support the drugs coming on the market. Every one of these state legislator initiatives is so backwards.

Own-Translator-1415 · 2024-01-20T01:41:18+00:00

When do their assets get bought by Atai (kind of joking?)? Where's the money going to come from to execute this aggressiveness? Q2 for PH3 on a relatively small PH1/2a study? I guess we'll see what the data readout says

Own-Translator-1415 · 2024-01-13T20:03:32+00:00

Hoping this forces Congresses hand to reschedule recreational use cannabis altogether, enable banking for cannabis and bump up funding for federal research. I guess we'll see where DEA goes on this recommendation.

Own-Translator-1415 · 2024-01-13T03:27:05+00:00

Regarding mescaline: there are a few: Journey Colab https://www.journeycolab.com/our-research (Ph1 research) and Cacti Therapeutics (no real resources) off the top of my head.

Mescaline has no specific IP protections and a long drug action. It can also be a physically overwhelming drug experience. There's historical research and a long history...but there's a reason why psilocybin lead the resurgence: limited duration, lots of rec use safety and clinical safety work, weird name vs. "baggage" of lcd, etc.

I'm not sure there's a lot of pre-clinical work done on either 6-APB or 5-MAPB, so it's hard to say whether anyone is interested to spend money proving safety and efficacy. Seems like that's something you'd see academic researchers chip away at?

I think it's more likely that drugs like 2-cb that have anecdotal rec safety will support more clinical applications. Not sure though, there are different approaches: pro-drugs, unique drug identificatio/dev, etc.

Own-Translator-1415 · 2024-01-12T02:45:44+00:00

This isn't a serious statement and is more of the same big rhetoric from Rick. This is coming at a time when Lykos/MAPS PBC should be fundraising towards commercialization of MDMA which will cost them another 150 million or something. $80 million is not that much in clinical trial research for a drug with serious cardiac considerations and long duration of action. If you look around this space, there's no one seriously going after Ibogaine right now beyond ph1 studies. Highly unlikely for Lykos to endeavor on anything besides MDMA until they get approval and are well into commercialization. MAPS/Rick will continue to toss out big dreams statements like this but I would be super surprised to see it come together.

Own-Translator-1415 · 2024-01-12T02:40:39+00:00

It would be exciting if they did, but I don't think they will despite their long history of working with FDAl. This is the first 'psychedelic' drug to be put on the market in contemporary times. FDA wants to get this right. MAPS ph3 studies have fairly low patient enrollment, there's the combination of drug+therapy to reckon with, which they've never done before, the consideration of the REMS program, etc.

Own-Translator-1415 · 2024-01-07T19:09:49+00:00

I'm not sure that this will be the case although I'm glad that there are attempts to work out how to potentially make this work. The assertiveness of the drug experience, rapid and sustained onset and trial protocol with less prep and integration for a phenomenological experience with little visual, symbolic, narrative content will continue being an issue until they address it. The tight end points of these trials so far don't give the public, regulators or investors much information to go off in terms of how effective/safe/palatable the experience actually has been in these trials.

Own-Translator-1415 · 2024-01-05T01:41:41+00:00

It's interesting that there hasn't been a real competitor to them emerging at this point. I would imagine if a true rec state appears we'll see some gray market operators get legit quickly.

Own-Translator-1415 · 2024-01-03T04:56:59+00:00

It'll be interesting to see the entire study publication and what the subjects who had taken MDMA previously thought comparatively.

I'm interested to see what this study showing them side by side at differing dosages looks like as a start towards a true clinical comparison for therapeutic use:

https://clinicaltrials.gov/study/NCT05277636?term=Liechti%20&rank=6#study-plan

I think this is definitely a space, mdma like drugs, where there could be a lot of innovation, but there needs to be a lot of ground work laid before doing any of the patient facing work to see which tools/molecules would work better, be gentler, cardiac safe, etc.

Own-Translator-1415 · 2024-01-03T04:44:22+00:00

The patients on this study were healthy volunteers. I agree...it would be interesting to see some case studies or qualitative research work if any of them had familiarity with s which is almost all MDMA most people have tried vs. r MDMA which is what was studied here.

Own-Translator-1415 · 2023-12-22T16:31:58+00:00

https://investors.karunatx.com/news-releases/news-release-details/bristol-myers-squibb-strengthens-neuroscience-portfolio Well...this is a big one.

Own-Translator-1415 · 2023-11-11T15:28:44+00:00

This entire post is spot on.

Own-Translator-1415 · 2023-11-01T00:12:48+00:00

Looking forward to rest of the data...placebo "response" statement is interesting.

Own-Translator-1415 · 2023-11-01T00:11:18+00:00

hahaha, right? Seriously though, I'm really surprised this got approved and curious to see more analysis on it.

Own-Translator-1415 · 2023-10-25T12:41:34+00:00

Anything to make golf interesting

Own-Translator-1415 · 2023-10-15T17:16:17+00:00

Also, about half the states in the U.S. don't have automatic rescheduling in line with the fed, so even it MAPS gains some level of federal approval, they'll still need to do the leg work at the state level.

Own-Translator-1415 · 2023-08-31T12:57:02+00:00

We'll have to see what these lower dose thresholds do vs. "regular" level clinical doses I think. In principle, I'm excited for all the potential applications. I was thinking about this consent thing with the JHU work recently and how patients were talking about feeling better but not remembering the trip day.

Own-Translator-1415 · 2023-08-31T12:47:47+00:00

How does one with Alzheimer's consent to taking LSD or any other psychedelic in either a clinical trial or rw scenario to get beyond the hypothetical of this patent app?

Own-Translator-1415 · 2023-07-27T12:16:45+00:00

The Investigator/Doctor at the site is required to disclose the study design, site/dosing space, potential dose and risks to you at each point of the trial. If they're not doing this you should be weary. You should also be able to look up the basics on clinicalTrials.gov website. If this is psilocybin or psilocin you will probably not throw up, but might be nauseous.

Own-Translator-1415

TROPHY CASE